ArticleTranslational lung cancer research2025
The difference in tumor immune microenvironment and IFN-γ response between solid and non-solid adenocarcinoma.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Solid subtype adenocarcinomas have poor prognosis. Interferon-γ (IFN-γ) is a critical cytokine related to anti-tumor response in the tumor immune microenvironment. We aimed to identify the prognostic factors related to IFN-γ responsiveness. Methods: A total of 112 lung adenocarcinoma samples were obtained from patients who underwent surgery between 2014 and 2020. DNA and RNA were extracted and analyzed. Additionally, the Cancer Genome Atlas dataset of patients with lung cancer was accessed. We classified adenocarcinomas using single-sample gene set enrichment analysis based on IFN-γ response pathway expression to elucidate the genomic profile and prognosis. Results: The tumor immune microenvironment is immunologically hot, with higher immune cell infiltration in the solid subtype than in the non-solid subtype. The patients were divided into two groups [Gene Ontology Biological Process-Interferon-Gamma (GOBP-IFNG) high and low] according to IFN-γ response pathway expression. In the solid subtype, the GOBP-IFNG-low group showed poorer overall survival (OS) than the GOBP-IFNG-high group. Multivariate analysis demonstrated that low GOBP-IFNG level was an independent poor prognostic factor. The apoptosis score and MHC class II expression levels were lower in the low-GOBP-IFNG group than those in the high-GOBP-IFNG group. A proliferation assay using solid subtype adenocarcinoma cell lines demonstrated that one of the three cell lines did not respond to IFN-γ. The copy number alteration (CNA) in the low-GOBP-IFNG group was higher than that in the high-GOBP-IFNG group in the solid subtype. Conclusions: Solid subtype adenocarcinomas are immunologically prevalent. IFN-γ response pathway expression is associated with the OS of solid subtype adenocarcinoma and may provide key insights to improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.